Quote | Aligos Therapeutics Inc. (NASDAQ:ALGS)
Last: | $0.35 |
---|---|
Change Percent: | 0.9% |
Open: | $0.375 |
Close: | $0.35 |
High: | $0.383999 |
Low: | $0.3482 |
Volume: | 2,480,847 |
Last Trade Date Time: | 06/28/2024 03:00:00 am |
News | Aligos Therapeutics Inc. (NASDAQ:ALGS)
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive...
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced six abstr...
Message Board Posts | Aligos Therapeutics Inc. (NASDAQ:ALGS)
Subject | By | Source | When |
---|---|---|---|
$ALGS 4Q22 results12/31/22 cash=$126M4Q22 cash_burn=$16M: | DewDiligence | investorshub | 03/09/2023 9:45:09 PM |
$ALGS de-prioritizes HBV programreduces workforce 10%: | DewDiligence | investorshub | 02/08/2023 11:09:44 PM |
znewcar1: $ALGS 23% v4,7M c2.02 f42,815M H2.41 ML.84 gapNgo to HOD | znewcar1 | investorshangout | 01/17/2023 10:14:56 PM |
Might hit $3 today. | Laster | investorshub | 01/17/2023 3:08:08 PM |
Beautiful. Will pass $2 today. | Laster | investorshub | 01/17/2023 12:41:36 PM |
News, Short Squeeze, Breakout and More Instantly...
Aligos Therapeutics Inc. Company Name:
ALGS Stock Symbol:
NASDAQ Market:
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive...
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced six abstr...
Topline data now projected in early Q4 2024 Rohit Loomba, MD, MHSc to serve as Principal Investigator SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused ...